f Post-Approval Studies (PAS) Database
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


New Enrollment Study for NovoTTF-100A

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Redesigned/Replaced Study
Application Number /
Requirement Number
P100034 / PAS001
Date Original Protocol Accepted 04/08/2011
Date Current Protocol Accepted 02/09/2016
Study Name New Enrollment Study for NovoTTF-100A
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives The study is a prospective, non-randomized open-label concurrent control study of NovoTTF-100A in recurrent GBM patients. A prospective, international, multi-center study, will include 30 centers in the US, EU and Israel, at least 15 centers in the US.

The study will include 2 groups: an Investigational Group composed of patients treated with the NovoTTF-100A and a Control Group of concurrent best standard of care chemotherapy.
Patients in the NovoTTF-100A group will be treated continuously until disease progression and then followed by telephone interview until death. Minimal recommended treatment duration is 4 weeks and minimal recommended treatment compliance is 18h/day (monthly average).
Study Population The NovoTTF-100A System is intended as a treatment for adult
patients (22 years of age or older) with histologically-confirmed
glioblastoma multiforme (GBM), following histologically- or
radiologically-confirmed recurrence in the supra-tentorial
region of the brain after receiving chemotherapy.

NovoTTF-100A Group
¿ Patients treated with the NovoTTF-100A
¿ Patients will be treated continuously until disease
¿ Minimal recommended treatment duration ¿ 4 weeks
¿ Minimal recommended treatment compliance ¿ 18h a day
(monthly average)

Control Group
¿ Concurrent best standard of care chemotherapy (control) group
Sample Size 30 centers in the US, EU and Israel. At least 15 centers in the

Test arm: N1=243 NovoTTF-100A patients
Comparator arm: N2=243 Concurrent best standard of care
control patients

λ1 = hazard of death in the test arm
λ2 = hazard of death in the comparator arm
Primary Statistical Hypothesis:
H0: λ1 / λ2 > 1.375
H1: λ1 / λ2 ≤ 1.375
Type I error: 0.05
Power: 0.80
Test statistics: Log-rank test
Lost to follow-up: 10%
Key Study Endpoints Primary
¿ Overall survival (months)

¿ Change in neuro-cognitive function from baseline based on the MMSE
¿ Genetic profiling of tumors and correlation with response
to NovoTTF-100A treatment, specifically:
o MGMT promoter methylation status
o EGFR amplification, over expression or rearrangement
o Chromosomes 1p/19q deletion status
o IDH1 mutation
¿ Adverse event incidence by body system and term,
o Incidence of seizures and headaches
o Anticonvulsant use
Follow-up Visits and Length of Follow-up ¿ Recruitment: 48 months
¿ Follow-up: 12 months from recruitment of last patient
¿ NovoTTF-100A treatment until clinical disease progression.
¿ Patients will continue to be followed until death
¿ Eligibility assessment
¿ Genetic profiling of tumor tissue
¿ Adverse event symptoms
¿ Concomitant medication
Monthly until clinical disease progression:
¿ Vital status
¿ Adverse event record
¿ Concomitant medication (including steroid and anticonvulsant
¿ Evaluation of progression
Monthly after disease progression:
¿ Vital status

New Enrollment Study for NovoTTF-100A Reporting Schedule

Reporting Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
six month report 10/07/2011 11/28/2011 Overdue/Received
one year report 04/07/2012 06/13/2012 Overdue/Received
18 month report 10/06/2012 10/26/2012 Overdue/Received
two year report 05/08/2013 05/02/2013 On Time
three year report 04/07/2014 08/08/2014 Overdue/Received
four year report 04/07/2015 04/20/2015 Overdue/Received

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources